Oxytrol Switch For OAB Surfaces Questions On Delayed Diagnoses
This article was originally published in The Pink Sheet Daily
Merck’s application to switch the overactive bladder drug Oxytrol for Women must prove to FDA’s OTC advisors that women suffering urinary incontinence due to urinary tract infections, diabetes or other conditions appropriately can discontinue treatment and seek medical attention.
You may also be interested in...
Merck, NDAC Chair Neill Cross Paths Again For Oxytrol Switch Meeting
Nonprescription Drugs Advisory Committee member Richard Neill in 2007 praised Merck’s Rx-to-OTC application for Mevacor while voting against the statin switch. On Nov. 9, Merck will try to convince now-chairman Neill and the rest of NDAC that overactive bladder drug Oxytrol can safely be sold OTC.
Asthma Treatment OTC Switches Would Face Tough Barriers
Prescription asthma drugs on the brink of patent expiry could breathe new life into Rx-to-OTC switches, but not without fierce opposition from some health care providers.
NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.